TRI
TRIVARX LTD
$0.0100
▼ -9.09%
Market cap
$12M
Turnover
$8,261
Last price
$0.0100
Day change
-9.09%
Announcements
9
Range, past year
Open 0.011 · Low 0.007 · Now 0.010 · High 0.035
Open TRI in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
TRI momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
33/100
Wyckoff phase
Downtrend13d
Trend stage
Breakdown
1 Day
-9.1%
1 Week
-16.7%
1 Month
-33.3%
1 Year
+0.0%
RSI
35
Avg daily range
11.6%
TRIVARX LTD scores 33 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Breakdown.
On the Wyckoff cycle it sits in Downtrend, where it has been for 13 trading days. The weekly timeframe reads Downtrend, which agrees with the daily view.
Against the wider market it is currently underperforming and the institutional accumulation signal reads low.
What stands out
- Trend R² 0.84 — highly linear uptrend
- Volume 1.8× 60-day avg
Points to watch
- 60d drawdown -55.0%
- High volatility (ATR 11.6%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsTRI announcements
Recent price-sensitive releases.
- 2026-09-23 Stabl-Im Clinical Development Update Progress Report
- 2026-08-27 Appendix 4E - Preliminary Final Report Preliminary Final Report
- 2026-07-28 June 2026 Quarterly Activities Report and Appendix 4C Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-07-16 Stabl-Im clinical trial supply milestone achieved
- 2026-05-22 CRO Engaged to Advance Stabl-Im Phase 1 Trial
- 2026-04-30 March 2026 Quarterly Activities Report and Appendix 4C
- 2026-04-29 Dr Danielle Meyrick appointed as CEO
More Health Care stocks
Most traded in the same sector.